Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells

被引:39
作者
Alawin, Osama A. [1 ]
Ahmed, Rayan A. [1 ]
Ibrahim, Baher A. [1 ]
Briski, Karen P. [1 ]
Sylvester, Paul W. [1 ]
机构
[1] Univ Louisiana Monroe, Sch Pharm, Monroe, LA 71209 USA
关键词
gamma-Tocotrienol; HER2; Lipid raft; Breast cancer; Caveolin-1; MAMMARY-TUMOR CELLS; GROWTH-FACTOR RECEPTOR; ERBB SIGNALING NETWORK; EPITHELIAL-CELLS; IN-VIVO; VITAMIN-E; APOPTOSIS; PROLIFERATION; ACTIVATION; THERAPY;
D O I
10.1016/j.jnutbio.2015.09.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
A large percentage of human breast cancers are characterized by excessive or aberrant HER2 activity. Lipid rafts are specialized microdomains within the plasma membrane that are required for HER2 activation and signal transduction. Since the anticancer activity of gamma-tocotrienol is associated with suppression in HER2 signaling, studies were conducted to examine the effects of gamma-tocotrienol on HER2 activation within the lipid raft microdomain in HER2-positive SKBR3 and BT474 human breast cancer cells. Treatment with 0-5 mu M gamma-tocotrienol induced a significant dose-dependent inhibition in cancer cell growth after a 5-day culture period, and these growth inhibitory effects were associated with a reduction in HER2 dimerization and phosphorylation (activation). Phosphorylated HER2 was found to be primarily located in the lipid raft microdomain of the plasma membrane in vehicle-treated control groups, whereas gamma-tocotrienol treatment significantly inhibited this effect. Assay of plasma membrane subcellular fractions showed that gamma-tocotrienol also accumulates exclusively within the lipid raft microdomain. Hydroxypropyl-beta-cyclodextrin (HP beta CD) is an agent that disrupts lipid raft integrity. Acute exposure to 3 mM HP beta CD alone had no effect, whereas an acute 24-h exposure to 20 mu M gamma-tocotrienol alone significantly decreased SKBR3 and BT474 cell viability. However, combined treatment with these agents greatly reduced gamma-tocotrienol accumulation in the lipid raft microdomain and cytotoxicity. In summary, these findings demonstrate that the anticancer effects of gamma-tocotrienol are associated with its accumulation in the lipid raft microdomain and subsequent interference with HER2 dimerization and activation in SKBR3 and BT474 human breast cancer cells. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:266 / 277
页数:12
相关论文
共 57 条
[1]
The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells [J].
Adachi, Seiji ;
Nagao, Tomokazu ;
Ingolfsson, Helgi I. ;
Maxfield, Frederick R. ;
Andersen, Olaf S. ;
Kopelovich, Levy ;
Weinstein, I. Bernard .
CANCER RESEARCH, 2007, 67 (13) :6493-6501
[2]
Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies [J].
Alqahtani, Saeed ;
Alayoubi, Alaadin ;
Nazzal, Sami ;
Sylvester, Paul W. ;
Kaddoumi, Amal .
AAPS JOURNAL, 2013, 15 (03) :684-695
[3]
Ananthula S, 2014, ANTICANCER RES, V34, P2715
[4]
Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells [J].
Atger, VM ;
Moya, MD ;
Stoudt, GW ;
Rodrigueza, WV ;
Phillips, MC ;
Rothblat, GH .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04) :773-780
[5]
Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration [J].
Ayoub, N. M. ;
Akl, M. R. ;
Sylvester, P. W. .
CELL PROLIFERATION, 2013, 46 (05) :538-553
[6]
γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells [J].
Ayoub, N. M. ;
Bachawal, S. V. ;
Sylvester, P. W. .
CELL PROLIFERATION, 2011, 44 (06) :516-526
[7]
Bachawal SV, 2010, ANTICANCER RES, V30, P429
[8]
Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells [J].
Bachawal, Sunitha V. ;
Wali, Vikram B. ;
Sylvester, Paul W. .
BMC CANCER, 2010, 10
[9]
Treatment of HER2-overexpressing breast cancer [J].
Baselga, J. .
ANNALS OF ONCOLOGY, 2010, 21 :36-40
[10]
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].
Baselga, Jose ;
Swain, Sandra M. .
NATURE REVIEWS CANCER, 2009, 9 (07) :463-475